IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9630976 B1

PDFFull Text
Date of Patent:
Apr. 25, 2017

Filed:

Jul. 02, 2013

Compound having agonistic activity on somatostatin receptor, and use thereof for medical purposes

Applicant:

Ono Pharmaceutical Co., Ltd., Osaka, JP;

Inventors:

Akiharu Ishida, Osaka, JP;

Takeshi Matsushita, Osaka, JP;

Tetsuya Sekiguchi, Osaka, JP;

Tatsuya Komagata, Osaka, JP;

Takuya Nishio, Osaka, JP;

Assignee:

ONO PHARMACEUTICAL CO., LTD., Osaka-shi, JP;

Attorney:

Sughrue Mion, PLLC

Primary Examiner:

Noble Jarrell

Assistant Examiner:

Ben S Michelson

Int. Cl.
CPC ...
A61K 31/445 (2006.01); C07D 211/68 (2006.01); C07D 211/80 (2006.01); C07D 213/02 (2006.01); C07D 498/04 (2006.01); C07D 401/04 (2006.01); A61K 31/4545 (2006.01); C07D 401/14 (2006.01); C07D 405/14 (2006.01); A61K 31/5383 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
C07D 498/04 (2013.01); A61K 31/4545 (2013.01); A61K 31/5383 (2013.01); A61K 45/06 (2013.01); C07D 401/04 (2013.01); C07D 401/14 (2013.01); C07D 405/14 (2013.01);
Abstract

Provision of orally-available and low-toxic somatostatin receptor subtype 2 agonist. Since the compound represented by the general formula (I): [wherein all symbols represent the same meanings as those described in the description] a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof is non-peptidic low-molecular compound which has strong somatostatin receptor subtype 2 agonist activity, the compound is orally-available. Additionally, since the compound is low-toxic, the compound is useful for the prevention and/or treatment of the somatostatin related diseases such as acromegaly or gastrointestinal obstruction.

Find Patent Forward Citations

Loading…